Home > Boards > US Listed > Biotechs > iBio, Inc. (IBIO)

Those snip snips you keep throwing out must

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Kraken3 Member Profile
 
Followed By 24
Posts 622
Boards Moderated 0
Alias Born 02/07/14
160x600 placeholder
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 4:30:00 PM
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021 GlobeNewswire Inc. - 9/20/2021 7:30:00 AM
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/7/2021 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/31/2021 4:31:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/26/2021 7:11:29 AM
iBio Appoints William D. Clark to its Board of Directors GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics GlobeNewswire Inc. - 8/25/2021 7:30:00 AM
iBio says successful in preclinical studies for subunit COVID-19 vaccine candidate Seeking Alpha - 7/16/2021 7:24:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/16/2021 6:04:34 AM
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate GlobeNewswire Inc. - 7/15/2021 5:10:00 PM
iBio establishes oncology drug discovery pipeline with three new antibody programs Seeking Alpha - 7/8/2021 4:23:04 PM
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs GlobeNewswire Inc. - 7/8/2021 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/9/2021 5:20:28 PM
iBio adds veteran biopharmaceutical executive to board of directors Seeking Alpha - 6/9/2021 4:44:08 PM
iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink GlobeNewswire Inc. - 6/9/2021 4:30:00 PM
iBio to Present at the UBS Global Healthcare Virtual Conference GlobeNewswire Inc. - 5/19/2021 4:30:00 PM
iBio Q1 net loss widens as expenses soar year-over-year; shares fall 6% Seeking Alpha - 5/17/2021 10:08:32 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2021 7:16:10 AM
iBio revenue in-line Seeking Alpha - 5/17/2021 7:04:02 AM
iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/17/2021 7:00:00 AM
iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021 GlobeNewswire Inc. - 5/10/2021 8:15:00 AM
ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action Seeking Alpha - 5/7/2021 8:57:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 4:46:04 PM
iBio shares surge on COVID-19 study update Seeking Alpha - 5/6/2021 4:42:34 PM
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program GlobeNewswire Inc. - 5/6/2021 4:15:00 PM
Kraken3   Wednesday, 10/29/14 01:28:43 PM
Re: thecrusher2011 post# 9243
Post # of 26315 
Those snip snips you keep throwing out must be your brain cells falling out of your head. IBIO does not own any drug associated with Ebola. Their patent covers the process that cures derivatives of the tobacco plant in order to process a drug called ZMapp (the most effective treatment of Ebola). Any company who attempts to use this process (which is the only viable way yet known to produce ZMapp on a large scale) will have to have permission in some form from IBIO. This is a fact. They do not own the drug or anything else related to Ebola. But they will benefit from the production of ZMapp just because of the process related to making it. Next financials will show this IMO.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences